{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:07:22Z","timestamp":1789002442822,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":78,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025A1515012402"],"award-info":[{"award-number":["2025A1515012402"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272985"],"award-info":[{"award-number":["82272985"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Projects in Guangzhou","award":["2024A03J0897"],"award-info":[{"award-number":["2024A03J0897"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Biol Lett"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Survival rates for ovarian cancer drop sharply at late-stages due to late diagnosis. Although PARP inhibitors are effective in homologous recombination-deficient (HRD) tumors, their efficacy in homologous recombination (HR)-proficient ovarian cancer remains limited, highlighting the need for novel molecular targets to inhibit tumor progression and improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Differentially expressed piRNAs were screened using ovarian cancer tissues from early- and advanced-stage patients. Functional studies were performed in ovarian cancer cell lines, xenograft models, and patient-derived organoids. Molecular mechanisms were investigated using RNA pulldown, RNA immunoprecipitation, MeRIP-seq, ubiquitination assays, and DNA damage analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified piR-26681 as a piRNA significantly downregulated in advanced-stage ovarian cancer and associated with favorable prognosis. Functional assays demonstrated that piR-26681 suppressed ovarian cancer progression in cell lines, xenograft mouse models, and patient-derived organoids. Mechanistically, piR-26681 directly interacted with METTL3 and METTL14, enhancing their interaction, reducing their ubiquitination, and thereby increasing their protein stability. This stabilization promoted global m\n                      <jats:sup>6<\/jats:sup>\n                      A methylation in ovarian cancer cells. Increased m\n                      <jats:sup>6<\/jats:sup>\n                      A modification subsequently enhanced the stability of FBXO16 mRNA through the m\n                      <jats:sup>6<\/jats:sup>\n                      A reader IGF2BP2, leading to elevated FBXO16 expression. As an E3 ubiquitin ligase, FBXO16 further mediated the ubiquitination and degradation of MORF4L1, a key regulator of homologous recombination repair. Loss of MORF4L1 impaired HR repair, increased DNA damage accumulation, and sensitized ovarian cancer cells to the PARP inhibitor niraparib.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study identifies a novel piR-26681\u2013METTL3\/METTL14\u2013FBXO16\u2013MORF4L1 regulatory axis that impairs DNA repair and suppresses ovarian cancer progression. piR-26681 represents a promising therapeutic target for sensitizing HR-proficient ovarian cancers to DNA-damaging therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s11658-026-00969-x","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:44:32Z","timestamp":1782323072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["piR-26681 suppresses ovarian cancer progression by enhancing METTL3\/METTL14-mediated m6A modification of FBXO16 and impairing DNA repair via MORF4L1 degradation"],"prefix":"10.1186","volume":"31","author":[{"given":"Jie-Lin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Hua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Juan","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Chun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Chen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"issue":"23","key":"969_CR1","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMe2116353","volume":"385","author":"GJ Gardner","year":"2021","unstructured":"Gardner GJ, Chi DS. Recurrent ovarian cancer\u2014Sculpting a promising future with surgery. N Engl J Med. 2021;385(23):2187\u20138.","journal-title":"N Engl J Med"},{"issue":"11","key":"969_CR2","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1001\/jamaoncol.2021.4131","volume":"7","author":"C Falandry","year":"2021","unstructured":"Falandry C, Freyer G, Pujade-Lauraine E. What is the optimal treatment for vulnerable older women with ovarian cancer?-reply. JAMA ONCOL. 2021;7(11):1727.","journal-title":"JAMA ONCOL"},{"issue":"2","key":"969_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/jnci\/djab151","volume":"114","author":"AW Kurian","year":"2022","unstructured":"Kurian AW, Abrahamse P, Bondarenko I, Hamilton AS, Deapen D, Gomez SL, et\u00a0al. Association of genetic testing results with mortality among women with breast cancer or ovarian cancer. J Natl Cancer Inst. 2022;114(2):245\u201353.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"969_CR4","doi-asserted-by":"publisher","first-page":"972","DOI":"10.6004\/jnccn.2022.0047","volume":"20","author":"DK Armstrong","year":"2022","unstructured":"Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, et\u00a0al. NCCN guidelines\u00ae insights: ovarian cancer, version 3.2022. J Natl Compr Canc Netw. 2022;20(9):972\u201380.","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"969_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.21037\/cco-20-34","volume":"9","author":"P Gaona-Luviano","year":"2020","unstructured":"Gaona-Luviano P, Medina-Gaona LA, Maga\u00f1a-P\u00e9rez K. Epidemiology of ovarian cancer. Chin Clin Oncol. 2020;9(4):47.","journal-title":"Chin Clin Oncol"},{"issue":"6","key":"969_CR6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jogoh.2019.03.017","volume":"48","author":"V Lavoue","year":"2019","unstructured":"Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, et\u00a0al. Management of epithelial cancer of the ovary, Fallopian tube, and primary peritoneum. Long text of the Joint French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa. Part 1: Diagnostic exploration and staging, surgery, perioperative care, and pathology. J Gynecol Obstet Hum Reprod. 2019;48(6):369\u201378.","journal-title":"J Gynecol Obstet Hum Reprod"},{"issue":"7099","key":"969_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nature04916","volume":"442","author":"A Aravin","year":"2006","unstructured":"Aravin A, Gaidatzis D, Pfeffer S, Lagos-Quintana M, Landgraf P, Iovino N, et\u00a0al. A novel class of small RNAs bind to MILI protein in mouse testes. Nature. 2006;442(7099):203\u20137.","journal-title":"Nature"},{"issue":"5785","key":"969_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1126\/science.1130164","volume":"313","author":"NC Lau","year":"2006","unstructured":"Lau NC, Seto AG, Kim J, Kuramochi-Miyagawa S, Nakano T, Bartel DP, et\u00a0al. Characterization of the piRNA complex from rat testes. Science. 2006;313(5785):363\u20137.","journal-title":"Science"},{"issue":"1","key":"969_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1052-9","volume":"18","author":"Y Liu","year":"2019","unstructured":"Liu Y, Dou M, Song X, Dong Y, Liu S, Liu H, et\u00a0al. The emerging role of the piRNA\/piwi complex in cancer. Mol Cancer. 2019;18(1):123.","journal-title":"Mol Cancer"},{"key":"969_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202414398","author":"R Wang","year":"2025","unstructured":"Wang R, Li F, Lin Y, Lu Z, Luo W, Xu Z, et\u00a0al. piR-RCC suppresses renal cell carcinoma progression by facilitating YBX-1 cytoplasm localization. Adv Sci. 2025. https:\/\/doi.org\/10.1002\/advs.202414398.","journal-title":"Adv Sci"},{"issue":"25","key":"969_CR11","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonzalez-Martin","year":"2019","unstructured":"Gonzalez-Martin A, Pothuri B, Vergote I, DePont CR, Graybill W, Mirza MR. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391\u2013402.","journal-title":"N Engl J Med"},{"issue":"7353","key":"969_CR12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609\u201315.","journal-title":"Nature."},{"key":"969_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051206","author":"S Bouberhan","year":"2020","unstructured":"Bouberhan S, Philp L, Hill S, Al-Alem LF, Rueda B. Exploiting the prevalence of homologous recombination deficiencies in high-grade serous ovarian cancer. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12051206.","journal-title":"Cancers (Basel)"},{"issue":"27","key":"969_CR14","doi-asserted-by":"publisher","first-page":"5275","DOI":"10.1016\/j.febslet.2007.10.017","volume":"581","author":"SN Garcia","year":"2007","unstructured":"Garcia SN, Kirtane BM, Podlutsky AJ, Pereira-Smith OM, Tominaga K. Mrg15 null and heterozygous mouse embryonic fibroblasts exhibit DNA-repair defects post exposure to gamma ionizing radiation. Febs Lett. 2007;581(27):5275\u201381.","journal-title":"Febs Lett"},{"issue":"5","key":"969_CR15","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/s41401-023-01211-6","volume":"45","author":"N Jiang","year":"2024","unstructured":"Jiang N, Li YB, Jin JY, Guo JY, Ding QR, Meng D, et\u00a0al. Structural and functional insights into the epigenetic regulator MRG15. Acta Pharmacol Sin. 2024;45(5):879\u201389.","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"969_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.molcel.2020.06.017","volume":"79","author":"C Zhang","year":"2020","unstructured":"Zhang C, Chen L, Peng D, Jiang A, He Y, Zeng Y, et\u00a0al. METTL3 and N6-methyladenosine promote homologous recombination-mediated repair of DSBs by modulating DNA-RNA hybrid accumulation. Mol Cell. 2020;79(3):425\u201342.","journal-title":"Mol Cell"},{"issue":"1","key":"969_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-020-07291-6","volume":"21","author":"X Pan","year":"2020","unstructured":"Pan X, Fang Y, Li X, Yang Y, Shen HB. RBPsuite: RNA-protein binding sites prediction suite based on deep learning. BMC Genom. 2020;21(1):884.","journal-title":"BMC Genom"},{"issue":"2","key":"969_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nchembio.1432","volume":"10","author":"J Liu","year":"2014","unstructured":"Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, et\u00a0al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014;10(2):93\u20135.","journal-title":"Nat Chem Biol"},{"issue":"1","key":"969_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01435-9","volume":"9","author":"Y Xu","year":"2023","unstructured":"Xu Y, Zhang Y, Luo Y, Qiu G, Lu J, He M, et\u00a0al. Novel insights into the METTL3-METTL14 complex in musculoskeletal diseases. Cell Death Discov. 2023;9(1):170.","journal-title":"Cell Death Discov"},{"issue":"9","key":"969_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024657","volume":"6","author":"BG Pierce","year":"2011","unstructured":"Pierce BG, Hourai Y, Weng Z. Accelerating protein docking in ZDOCK using an advanced 3D convolution library. PLoS ONE. 2011;6(9):e24657.","journal-title":"PLoS ONE"},{"issue":"7608","key":"969_CR21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nature18298","volume":"534","author":"X Wang","year":"2016","unstructured":"Wang X, Feng J, Xue Y, Guan Z, Zhang D, Liu Z, et\u00a0al. Structural basis of N(6)-adenosine methylation by the METTL3-METTL14 complex. Nature. 2016;534(7608):575\u20138.","journal-title":"Nature"},{"issue":"2","key":"969_CR22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/ncb2902","volume":"16","author":"Y Wang","year":"2014","unstructured":"Wang Y, Li Y, Toth JI, Petroski MD, Zhang Z, Zhao JC. N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells. Nat Cell Biol. 2014;16(2):191\u20138.","journal-title":"Nat Cell Biol"},{"issue":"3","key":"969_CR23","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202255762","volume":"24","author":"ZC Zeng","year":"2023","unstructured":"Zeng ZC, Pan Q, Sun YM, Huang HJ, Chen XT, Chen TQ, et\u00a0al. METTL3 protects METTL14 from STUB1-mediated degradation to maintain m(6) A homeostasis. EMBO Rep. 2023;24(3):EMBR202255762.","journal-title":"EMBO Rep"},{"issue":"9","key":"969_CR24","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.7150\/ijbs.69771","volume":"18","author":"J Chen","year":"2022","unstructured":"Chen J, Fang Y, Xu Y, Sun H. Role of m6A modification in female infertility and reproductive system diseases. Int J Biol Sci. 2022;18(9):3592\u2013604.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"969_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01231-5","volume":"15","author":"Q Guan","year":"2022","unstructured":"Guan Q, Lin H, Miao L, Guo H, Chen Y, Zhuo Z, et\u00a0al. Functions, mechanisms, and therapeutic implications of METTL14 in human cancer. J Hematol Oncol. 2022;15(1):13.","journal-title":"J Hematol Oncol"},{"key":"969_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.824258","volume":"12","author":"Y Li","year":"2022","unstructured":"Li Y, Peng H, Jiang P, Zhang J, Zhao Y, Feng X, et\u00a0al. Downregulation of Methyltransferase-Like 14 promotes ovarian cancer cell proliferation through stabilizing TROAP mRNA. Front Oncol. 2022;12:824258.","journal-title":"Front Oncol"},{"issue":"2","key":"969_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.rbmo.2022.10.010","volume":"46","author":"L Shen","year":"2023","unstructured":"Shen L, Zhang C, Zhang Y, Yang Y. METTL3 and METTL14-mediated N(6)-methyladenosine modification promotes cell proliferation and invasion in a model of endometriosis. Reprod Biomed Online. 2023;46(2):255\u201365.","journal-title":"Reprod Biomed Online"},{"issue":"1","key":"969_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-01799-x","volume":"21","author":"J Wang","year":"2021","unstructured":"Wang J, Chen L, Qiang P. The role of IGF2BP2, an m6A reader gene, in human metabolic diseases and cancers. Cancer Cell Int. 2021;21(1):99.","journal-title":"Cancer Cell Int"},{"issue":"D1","key":"969_CR29","doi-asserted-by":"publisher","first-page":"D92","DOI":"10.1093\/nar\/gkt1248","volume":"42","author":"J Li","year":"2013","unstructured":"Li J, Liu S, Zhou H, Qu L, Yang J. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein\u2013RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2013;42(D1):D92\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"969_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04040-9","volume":"12","author":"M Ji","year":"2021","unstructured":"Ji M, Zhao Z, Li Y, Xu P, Shi J, Li Z, et\u00a0al. FBXO16-mediated hnRNPL ubiquitination and degradation plays a tumor suppressor role in ovarian cancer. Cell Death Dis. 2021;12(8):758.","journal-title":"Cell Death Dis"},{"issue":"D1","key":"969_CR31","doi-asserted-by":"publisher","first-page":"D529","DOI":"10.1093\/nar\/gky1079","volume":"47","author":"R Oughtred","year":"2019","unstructured":"Oughtred R, Stark C, Breitkreutz BJ, Rust J, Boucher L, Chang C, et\u00a0al. The BioGRID interaction database: 2019 update. Nucleic Acids Res. 2019;47(D1):D529\u201341.","journal-title":"Nucleic Acids Res"},{"issue":"29","key":"969_CR32","doi-asserted-by":"publisher","first-page":"7671","DOI":"10.1073\/pnas.1620208114","volume":"114","author":"JY Bleuyard","year":"2017","unstructured":"Bleuyard JY, Fournier M, Nakato R, Couturier AM, Katou Y, Ralf C, et\u00a0al. MRG15-mediated tethering of PALB2 to unperturbed chromatin protects active genes from genotoxic stress. Proc Natl Acad Sci U S A. 2017;114(29):7671\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 7","key":"969_CR33","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1242\/jcs.060178","volume":"123","author":"T Hayakawa","year":"2010","unstructured":"Hayakawa T, Zhang F, Hayakawa N, Ohtani Y, Shinmyozu K, Nakayama J, et\u00a0al. MRG15 binds directly to PALB2 and stimulates homology-directed repair of chromosomal breaks. J Cell Sci. 2010;123(Pt 7):1124\u201330.","journal-title":"J Cell Sci"},{"issue":"2","key":"969_CR34","doi-asserted-by":"publisher","first-page":"R40","DOI":"10.1186\/bcr2862","volume":"13","author":"G Martrat","year":"2011","unstructured":"Martrat G, Maxwell CM, Tominaga E, Porta-de-la-Riva M, Bonifaci N, G\u00f3mez-Bald\u00f3 L, et\u00a0al. Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Res. 2011;13(2):R40.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"969_CR35","first-page":"284","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et\u00a0al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284\u201396.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"969_CR36","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nsmb.3162","volume":"23","author":"N Liu","year":"2016","unstructured":"Liu N, Pan T. N6-methyladenosine\u2013encoded epitranscriptomics. Nat Struct Mol Biol. 2016;23(2):98\u2013102.","journal-title":"Nat Struct Mol Biol"},{"issue":"3","key":"969_CR37","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020105977","volume":"40","author":"PC He","year":"2021","unstructured":"He PC, He C. m(6) A RNA methylation: from mechanisms to therapeutic potential. EMBO J. 2021;40(3):e105977.","journal-title":"EMBO J"},{"issue":"1","key":"969_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12967-022-03257-2","volume":"20","author":"Q Xie","year":"2022","unstructured":"Xie Q, Li Z, Luo X, Wang D, Zhou Y, Zhao J, et\u00a0al. piRNA-14633 promotes cervical cancer cell malignancy in a METTL14-dependent m6A RNA methylation manner. J Transl Med. 2022;20(1):51.","journal-title":"J Transl Med"},{"issue":"1","key":"969_CR39","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12964-023-01360-5","volume":"21","author":"Q Jin","year":"2023","unstructured":"Jin Q, Qu H, Quan C. New insights into the regulation of METTL3 and its role in tumors. Cell Commun Signal. 2023;21(1):334.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"969_CR40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13045-020-00951-w","volume":"13","author":"C Zeng","year":"2020","unstructured":"Zeng C, Huang W, Li Y, Weng H. Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol. 2020;13(1):117.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"969_CR41","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12943-020-01220-7","volume":"19","author":"X Chen","year":"2020","unstructured":"Chen X, Xu M, Xu X, Zeng K, Liu X, Pan B, et\u00a0al. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer. Mol Cancer. 2020;19(1):106.","journal-title":"Mol Cancer"},{"issue":"2","key":"969_CR42","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/hep.28885","volume":"65","author":"JZ Ma","year":"2017","unstructured":"Ma JZ, Yang F, Zhou CC, Liu F, Yuan JH, Wang F, et\u00a0al. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N(6) -methyladenosine-dependent primary MicroRNA processing. Hepatology. 2017;65(2):529\u201343.","journal-title":"Hepatology"},{"issue":"14","key":"969_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202413121","volume":"12","author":"X He","year":"2025","unstructured":"He X, Li Y, Li J, Li Y, Chen S, Yan X, et\u00a0al. HDAC2-mediated METTL3 delactylation promotes DNA damage repair and chemotherapy resistance in triple-negative breast cancer. Adv Sci (Weinh). 2025;12(14):e2413121.","journal-title":"Adv Sci (Weinh)"},{"issue":"7","key":"969_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112688","volume":"42","author":"K Miyake","year":"2023","unstructured":"Miyake K, Costa CP, Nagatomo I, Kato Y, Motooka D, Satoh S, et\u00a0al. A cancer-associated METTL14 mutation induces aberrant m6A modification, affecting tumor growth. Cell Rep. 2023;42(7):112688.","journal-title":"Cell Rep"},{"issue":"51","key":"969_CR45","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ads4750","volume":"10","author":"C Zhang","year":"2024","unstructured":"Zhang C, Scott RL, Tunes L, Hsieh MH, Wang P, Kumar A, et\u00a0al. Cancer mutations rewire the RNA methylation specificity of METTL3-METTL14. Sci Adv. 2024;10(51):s4750.","journal-title":"Sci Adv"},{"key":"969_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106162","volume":"178","author":"N Gupta","year":"2022","unstructured":"Gupta N, Huang TT, Horibata S, Lee JM. Cell cycle checkpoints and beyond: Exploiting the ATR\/CHK1\/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer. Pharmacol Res. 2022;178:106162.","journal-title":"Pharmacol Res"},{"issue":"1","key":"969_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01227-0","volume":"19","author":"H Li","year":"2020","unstructured":"Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer. 2020;19(1):107.","journal-title":"Mol Cancer"},{"key":"969_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121790","volume":"326","author":"Y Liu","year":"2023","unstructured":"Liu Y, Xue R, Duan X, Shang X, Wang M, Wang F, et\u00a0al. PARP inhibition synergizes with CD47 blockade to promote phagocytosis by tumor-associated macrophages in homologous recombination-proficient tumors. Life Sci. 2023;326:121790.","journal-title":"Life Sci"},{"key":"969_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/genes9070329","author":"F Morena","year":"2018","unstructured":"Morena F, Argentati C, Bazzucchi M, Emiliani C, Martino S. Above the epitranscriptome: RNA modifications and stem cell identity. Genes (Basel). 2018. https:\/\/doi.org\/10.3390\/genes9070329.","journal-title":"Genes (Basel)"},{"key":"969_CR50","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.pharmthera.2018.11.011","volume":"196","author":"AM Yu","year":"2019","unstructured":"Yu AM, Jian C, Yu AH, Tu MJ. RNA therapy: are we using the right molecules? Pharmacol Ther. 2019;196:91\u2013104.","journal-title":"Pharmacol Ther"},{"issue":"10","key":"969_CR51","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.7150\/thno.81604","volume":"13","author":"M Shui","year":"2023","unstructured":"Shui M, Chen Z, Chen Y, Yuan Q, Li H, Vong CT, et\u00a0al. Engineering polyphenol-based carriers for nucleic acid delivery. Theranostics. 2023;13(10):3204\u201323.","journal-title":"Theranostics"}],"container-title":["Cellular &amp; Molecular Biology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11658-026-00969-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-026-00969-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-026-00969-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:28:32Z","timestamp":1789000112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s11658-026-00969-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["969"],"URL":"https:\/\/doi.org\/10.1186\/s11658-026-00969-x","relation":{},"ISSN":["1689-1392"],"issn-type":[{"value":"1689-1392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethics Committee of Guangzhou Medical University (No: 2021\u2013055, date: May 2021) approved the use of human tissue in this study, which was conducted in accordance with the Declaration of Helsinki. All animal experiments were approved by the Guangdong Medical Laboratory Animal Center (Approval No. B202208-8) and were conducted in accordance with the guidelines of the International Council for Laboratory Animal Science (ICLAS).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"143"}}